Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Aura Biosciences (AURA) EBIAT (2020 - 2026)

Aura Biosciences filings provide 7 years of EBIAT readings, the most recent being -$33.7 million for Q1 2026.

  • Quarterly EBIAT fell 22.57% to -$33.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$112.4 million through Mar 2026, down 18.7% year-over-year, with the annual reading at -$106.2 million for FY2025, 22.18% down from the prior year.
  • EBIAT hit -$33.7 million in Q1 2026 for Aura Biosciences, down from -$25.6 million in the prior quarter.
  • Across five years, EBIAT topped out at -$12.8 million in Q1 2022 and bottomed at -$33.7 million in Q1 2026.
  • Average EBIAT over 5 years is -$21.3 million, with a median of -$20.3 million recorded in 2024.
  • The largest annual shift saw EBIAT tumbled 116.55% in 2022 before it rose 1.03% in 2025.
  • Aura Biosciences' EBIAT stood at -$16.6 million in 2022, then tumbled by 33.62% to -$22.1 million in 2023, then fell by 16.73% to -$25.8 million in 2024, then rose by 1.03% to -$25.6 million in 2025, then crashed by 31.75% to -$33.7 million in 2026.
  • Per Business Quant, the three most recent readings for AURA's EBIAT are -$33.7 million (Q1 2026), -$25.6 million (Q4 2025), and -$26.1 million (Q3 2025).